Drugs / Dendritic Cell Tumor Fusion Vaccine
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00459069 | Jul 2004 → Jun 2008 | plasma cell myeloma | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00458536 | Oct 2004 → Dec 2014 | kidney cancer | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dendritic Cell Tumor Fusion Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00458536 ↗ |
| Modality | Vaccine | “Dendritic Cell Tumor Fusion Vaccine” NCT00458536 ↗ |
| Route | Subcutaneous | “The treatment will consist of 3 vaccinations of fused cells given by an injection under your skin at 3-week intervals.” NCT00458536 ↗ |